UPCC 14825 GOG-3100: Collection of Biospecimens from Homologous Recombination Deficient (HRD) Test Negative High-Grade Serous Ovarian Cancer Patients

Enrolling By Invitation
99 years or below
All
Phase N/A
20 participants needed
1 Location

Brief description of study

Primary Objective
1. To explore genetic, proteomic, and molecular characteristics associated with recurrence less than six months following completion of frontline adjuvant combination platinum-based chemotherapy versus recurrence 18 months following completion of frontline adjuvant combination platinum-based chemotherapy. 2. To create a biorepository of tissue and blood that will be used in research studies designed to better understand the molecular biology of HRD test negative high-grade serous ovarian cancer. There are no statistical considerations for this study. Statistical justifications will be required for all requests to utilize biospecimens collected as part of this study. The purpose of this study is to explore genetic, proteomic, and molecular characteristics associated with recurrence. This study will also create a biorepository.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 22 Apr 2026. Study ID: 25-0810
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator